The Journal of clinical endocrinology and metabolism · 2026
Cigarette smoking exposure and clinical outcomes in Graves' disease.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Forbes Sarah, Loo May, Tee Su Ann, Stewart Kathryn, Vernazza Jonathan, Carroll Lauren, Vennart Nicholas, Bartholomew Peter, Narayanan Kilimangalam, Tsatlidis Vasileios, Razvi Salman
Аннотация
CONTEXT: Smoking is a recognized risk factor for Graves' disease (GD), but its quantitative relationship with disease severity, autoimmunity, and relapse after antithyroid drug (ATD) therapy is unclear.
OBJECTIVE: To evaluate the dose-dependent association between smoking exposure and key clinical outcomes in GD.
METHODS: This was a single-center observational cohort study conducted in a secondary-care endocrinology unit in the United Kingdom. Consecutive adults with newly diagnosed GD confirmed by suppressed TSH, elevated thyroid hormones, and positive TRAb or diffusely increased scintigraphic uptake were analysed. All 991 eligible patients were included in baseline analyses; 663 completed ≥12 months follow-up after ATD cessation, and 712 contributed to long-term relapse analyses. The main outcome measures were baseline TRAb levels, presence of orbitopathy, and relapse at 12 months and long term, defined as recurrent biochemical hyperthyroidism with elevated TRAb after ATD withdrawal. Other outcomes included additional biochemical, scintigraphic and clinical measures. Exposures were smoking status (non-, ex-, current smoker) and cigarettes/day.
RESULTS: Current smokers (27%) had higher TRAb levels at diagnosis (median 7.8 vs 6.6 IU/L in nonsmokers, P = .002) and increased odds of orbitopathy (OR 1.76, 95% CI 1.17-2.64). Each 10 cigarettes/day conferred a 34% (95% CI 10-79%) higher odds of orbitopathy and 60% higher 12-month relapse risk. Smokers also had higher TRAb at ATD cessation. In time-dependent Cox models, excess relapse risk among current smokers was greatest early after ATD withdrawal (HR 1.24 at 6 months) and diminished by 2 years. TRAb mediated only 7% of the smoking-relapse association.
CONCLUSION: Smoking is associated with greater autoimmune activity, higher orbitopathy risk, and increased relapse in a dose-dependent manner. Ex-smokers have risks comparable with nonsmokers, supporting cessation or reduction as a meaningful intervention to improve GD outcomes.
OBJECTIVE: To evaluate the dose-dependent association between smoking exposure and key clinical outcomes in GD.
METHODS: This was a single-center observational cohort study conducted in a secondary-care endocrinology unit in the United Kingdom. Consecutive adults with newly diagnosed GD confirmed by suppressed TSH, elevated thyroid hormones, and positive TRAb or diffusely increased scintigraphic uptake were analysed. All 991 eligible patients were included in baseline analyses; 663 completed ≥12 months follow-up after ATD cessation, and 712 contributed to long-term relapse analyses. The main outcome measures were baseline TRAb levels, presence of orbitopathy, and relapse at 12 months and long term, defined as recurrent biochemical hyperthyroidism with elevated TRAb after ATD withdrawal. Other outcomes included additional biochemical, scintigraphic and clinical measures. Exposures were smoking status (non-, ex-, current smoker) and cigarettes/day.
RESULTS: Current smokers (27%) had higher TRAb levels at diagnosis (median 7.8 vs 6.6 IU/L in nonsmokers, P = .002) and increased odds of orbitopathy (OR 1.76, 95% CI 1.17-2.64). Each 10 cigarettes/day conferred a 34% (95% CI 10-79%) higher odds of orbitopathy and 60% higher 12-month relapse risk. Smokers also had higher TRAb at ATD cessation. In time-dependent Cox models, excess relapse risk among current smokers was greatest early after ATD withdrawal (HR 1.24 at 6 months) and diminished by 2 years. TRAb mediated only 7% of the smoking-relapse association.
CONCLUSION: Smoking is associated with greater autoimmune activity, higher orbitopathy risk, and increased relapse in a dose-dependent manner. Ex-smokers have risks comparable with nonsmokers, supporting cessation or reduction as a meaningful intervention to improve GD outcomes.